3SBio Given OK for High-Dose EPIAO

3SBio reported the SFDA has approved its high-dose formulation of EPIAO, a treatment for chemotherapy-induced anemia. The high dose version allows once-a-week administration, a big advantage over the three-times-weekly protocol of the low-dose formulation of the drug. It’s been a long wait for the regulatory blessing: 3SBio said it filed for SFDA approval of EPIAO in December 1998. More details.... Stock Symbol: (NSDQ: SSRX)     Share this with colleagues: